Side-by-side comparison of AI visibility scores, market position, and capabilities
Fremont CA semiconductor etch and deposition (NASDAQ: LRCX) $14.9B FY2024 revenue; 3D NAND/HBM etch leader, 40%+ plasma etch share, $5B+ services revenue competing with Applied Materials and Tokyo Electron.
Lam Research Corporation is a Fremont, California-based semiconductor equipment company — publicly traded on the NASDAQ (NASDAQ: LRCX) as an S&P 500 Information Technology component — designing and manufacturing etch and deposition systems critical for semiconductor chip fabrication, providing products across plasma etch (removing material layers with precision), chemical vapor deposition (CVD — depositing thin films on wafers), atomic layer deposition (ALD — depositing single atomic layers with Angstrom-level precision), and related services through approximately 17,000 employees worldwide. In fiscal year 2024 (ending June 2024), Lam Research reported revenues of $14.9 billion, with strong revenue recovery driven by semiconductor industry capex expansion (NAND flash memory producers resuming equipment orders after the 2022-2023 memory market downturn, and DRAM producers expanding capacity for HBM — High Bandwidth Memory — required in NVIDIA AI GPU packages). CEO Tim Archer has positioned Lam Research as an "advanced process technology" partner rather than a pure equipment vendor: Lam's ALD-Select, VECTOR deposition, and Kiyo etch systems are co-developed with leading chipmakers (TSMC, Samsung, SK Hynix, Micron) for specific process nodes — creating application-specific systems optimized for 3nm logic, 1-alpha DRAM, and 200+ layer 3D NAND that require Lam's process understanding rather than generic equipment. Lam Research's Global Customer Support (GCS) organization provides equipment maintenance, spare parts, and process consulting services — generating $5+ billion annually in recurring service revenue that is less cyclical than equipment capital expenditure.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.